Adial Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Adial Pharmaceuticals, Inc. (ADIL) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-13.20-5.12-10.80-19.42-10.89
Depreciation & Amortization0.000.000.000.060.00
Deferred Income Tax0.000.000.00-0.090.00
Stock Based Compensation0.801.753.374.242.01
Change in Working Capital0.39-0.79-1.171.461.25
Change in Accounts Payable0.17-0.160.02-0.350.62
Change in Other Working Capital4.540.05-1.191.820.62
Other Operating Activities4.540.053.370.170.00
Net Cash from Operating Activities-6.92-6.81-11.19-11.95-7.63
Investing Activities
Capital Expenditures0.000.000.00-0.060.00
Acquisitions0.000.000.000.030.00
Other Investing Activities0.000.000.000.00-0.35
Net Cash from Investing Activities0.001.500.00-0.03-0.35
Financing Activities
Common Stock Issued4.020.759.1213.646.17
Common Stock Repurchased0.000.000.000.000.00
Other Financing Activities3.820.009.120.00-0.56
Net Cash from Financing Activities7.854.139.1313.645.61
Summary
Net Change in Cash0.92-1.17-2.061.66-2.38
Cash at Beginning of Period2.834.006.064.400.00
Cash at End of Period3.752.834.006.060.00
Free Cash Flow-6.92-6.81-11.19-12.01-7.63